Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
FAQ
- What is ImmunityBio, Inc.'s D&A?
- ImmunityBio, Inc. (IBRX) reported D&A of $4.38M in Q1 2026.
- How has ImmunityBio, Inc.'s D&A changed year-over-year?
- ImmunityBio, Inc.'s D&A increased by 14.4% year-over-year, from $3.83M to $4.38M.
- What is the long-term trend for ImmunityBio, Inc.'s D&A?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s D&A has grown at a 2.2% compound annual growth rate (CAGR), from $14.24M to $15.53M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about ImmunityBio, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude